Scynexis, Inc. (135A)

Overview

SCYNEXIS, Inc. is a biotechnology firm focused on the development of novel treatments for fungal infections. Based in the United States, more specifically in Jersey City, New Jersey, the company has established itself as a significant player in the industry since its inception in 1999. Originally founded as SCYNEXIS Chemistry & Automation, Inc., it underwent a name change to SCYNEXIS, Inc. in June 2002, marking a pivotal moment in its history towards a more focused biotechnological mission. SCYNEXIS, Inc. boasts a robust portfolio of collaborations with leading pharmaceutical companies such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. These partnerships underscore its commitment to advancing its drug development programs, particularly for its lead candidate, ibrexafungerp, and securing its commercialization rights across various global markets.

Products and Services

BREXAFEMME: A groundbreaking product by SCYNEXIS, BREXAFEMME is approved for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection, as well as recurrent VVC. It represents a significant advancement in the management of these common yet often distressing conditions, offering patients a new treatment option.

Ibrexafungerp: Leading the company's product pipeline, Ibrexafungerp is an innovative intravenous drug designed to combat a broad spectrum of fungal infections. Its potential applications are wide-ranging and include the treatment of invasive candidiasis, refractory invasive fungal infections, and invasive aspergillosis, in addition to VVC and recurrent VVC. The development of Ibrexafungerp underscores SCYNEXIS's commitment to addressing unmet medical needs in the area of antifungal treatments through cutting-edge research and development.